Safety and Administration Guidelines for Intravenous Iron Sucrose in Pregnancy

Timing and Safety Considerations

• Intravenous iron sucrose should be avoided before 13 weeks gestation; oral iron is recommended during the first trimester. 1
• After 13 weeks gestation, IV iron sucrose demonstrates an excellent safety profile with no serious adverse events reported in multiple randomized controlled trials of pregnant women. 1
• Resuscitation facilities must be immediately available for every infusion because anaphylaxis, although exceedingly rare (< 1 per 200 000 administrations), can occur. 1
• No fetal monitoring is required during or after IV iron administration. 1

Dosing and Administration Protocol

• Iron sucrose is administered as a 200 mg IV bolus over 10 minutes; this rapid protocol is licensed and preferred to the older 2‑hour infusion schedule. 2
• A test dose is not required for iron sucrose, unlike iron dextran which carries a 0.6–0.7 % risk of serious reactions and has been linked to 31 fatalities (1976‑1996). 2

Contraindicated Formulations

• Iron dextran should never be used in pregnancy because of its markedly higher anaphylactic risk and documented fatalities. 2

Monitoring After Treatment

• Iron parameters (e.g., serum iron, ferritin) should not be measured within 4 weeks of IV iron infusion, as circulating iron can produce spurious assay results.
• Hemoglobin should be reassessed 4 weeks after completing IV iron therapy, with an expected rise of ≥ 1 g/dL. 3
• Ferritin may be unreliable as a marker of iron stores in the presence of inflammation because it is an acute‑phase reactant. 4

Diagnostic Considerations in Pregnancy

• Hemoglobin or hematocrit alone should not be used to diagnose iron deficiency in pregnancy, since physiological hemodilution reduces their diagnostic accuracy. 4

Alternative Iron Formulations

• Ferric carboxymaltose allows a single 1000 mg dose over 15 minutes, reducing the number of clinic visits compared with iron sucrose. However, it is associated with treatment‑emergent hypophosphatemia and higher cost, and therefore should be avoided when repeat infusions are anticipated. 1

Intravenous Iron Sucrose Administration in Pregnancy

Indications

• In pregnant patients with moderate anemia (hemoglobin 7–10 g/dL) who have not responded to oral iron, intravenous iron sucrose is indicated, particularly when oral iron is poorly tolerated. 5

Dosing Protocol

• Each infusion delivers 200 mg of iron sucrose administered as a 10‑minute intravenous bolus; this rapid infusion is licensed and preferred over the older 2‑hour protocol. 6
• The maximum single dose is limited to 200 mg per treatment episode. 6
• Total iron requirement is calculated from hemoglobin and body weight: for a hemoglobin of 8.7 g/dL in pregnancy, the deficit is ≈ 1000 mg if body weight < 70 kg and ≈ 1500 mg if body weight ≥ 70 kg, corresponding to 5–8 infusions on alternate days until the calculated total is replaced. 5

Safety Precautions

• Resuscitation facilities must be immediately available during every infusion because anaphylaxis, although rare, can occur. 6
• No test dose is required for iron sucrose, unlike iron dextran which carries a higher anaphylactic risk. 6
• Newer formulations such as ferric carboxymaltose have no reported anaphylaxis, and iron sucrose itself has an excellent safety profile. 6

Monitoring After Therapy

• Serum ferritin should not be measured within 4 weeks after completing intravenous iron, as circulating iron can falsely elevate the assay. 7

Alternative Formulation: Ferric Carboxymaltose

• Ferric carboxymaltose permits a single dose up to 1000 mg delivered over 15 minutes, reducing the number of visits compared with iron sucrose (which requires 200 mg per infusion). 6

Risks of Iron Dextran

• Iron dextran preparations carry a 0.6–0.7 % risk of serious anaphylactic reactions and have been linked to 31 fatalities between 1976 and 1996; therefore, they should be avoided in pregnancy. 6

Cost Considerations

• The cost per gram of iron is substantially lower for iron sucrose (≈ £70.80) compared with ferric carboxymaltose (≈ £217.50), making iron sucrose a more cost‑effective option in most settings. 6